Clinical Trial

SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 26, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a n open-label, multi-center, phase II study to evaluate the efficacy and safety of SYS6010 combined with Enlonstobart in the recurrent or metastatic head and neck squamous cell carcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-25.
Status change: Not Yet Recruiting → Recruiting 2026-01-23
Trial Details
NCT Number NCT07254585
Lead Sponsor CSPC Megalith Biopharmaceutical Co.,Ltd.
Conditions Head and Neck Squamous Cell Carcinoma
Enrollment 70 participants
Start Date 2025-12-18
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-26